Cdc5l Antibody

What is Cdc5L and what are its main biological functions?

Cdc5L is a highly conserved spliceosomal protein that plays dual roles in cellular processes. Primarily, it functions as an essential component in pre-mRNA splicing, particularly during the second catalytic step which involves cleavage at the 3′ splice site and exon ligation, ultimately releasing the intact intron lariat . This processing ensures accurate mRNA production, which is critical for functional protein synthesis.

Additionally, Cdc5L serves as a cell cycle regulator, contributing to proper cell division. The protein contains two helix-turn-helix myb-type DNA-binding domains that enable its interaction with DNA and participation in splicing mechanisms . Recent studies have also implicated Cdc5L in various pathological processes, including cancer progression and chemoresistance .

Chromosomal aberrations involving Cdc5L have been linked to multicystic renal dysplasia, highlighting its importance in normal development . Furthermore, research has revealed its crucial role in regulating metaphase-to-anaphase I transition during oocyte meiotic maturation .

What types of Cdc5L antibodies are available for research applications?

Researchers can access several types of Cdc5L antibodies, with the most common being monoclonal antibodies like the D-11 clone. These antibodies are available in both non-conjugated forms and various conjugated formats to accommodate different experimental needs:

The selection of antibody format should be guided by experimental requirements. For instance, HRP-conjugated antibodies eliminate the need for secondary antibodies in western blotting, while fluorescent conjugates like FITC and PE allow direct visualization in immunofluorescence and flow cytometry applications .

How does Cdc5L contribute to cellular pathways in disease models?

In gastric cancer (GC) models, Cdc5L has been identified as a significant contributor to disease progression through several mechanisms:

• Proliferation enhancement: Cdc5L upregulation accelerates tumor cell proliferation through activation of cell cycle pathways .

• Chemoresistance promotion: Studies have demonstrated that Cdc5L suppression significantly inhibits GC cell proliferation when exposed to oxaliplatin, with knockdown experiments showing increased apoptosis rates in cells treated with this chemotherapeutic agent .

• MAPK pathway activation: Cdc5L directly interacts with MAPK1, forming a regulatory complex that enhances GC progression. This interaction was confirmed through co-immunoprecipitation and immunofluorescence assays showing colocalization in the nucleus .

• DNA damage response: Gene Set Enrichment Analysis indicates a positive correlation between Cdc5L expression and DNA damage response pathways, suggesting its role in maintaining genomic stability under stress conditions .

In reproductive biology, Cdc5L regulates oocyte maturation by facilitating the metaphase-to-anaphase I transition. Knockdown studies have revealed that Cdc5L deficiency causes metaphase I arrest and reduced first polar body extrusion, indicating its essential role in meiotic progression .

Which detection methods are most suitable for Cdc5L antibodies in different experimental contexts?

The choice of detection method depends on your research question and experimental system. Based on validated applications:

Western Blotting (WB): Recommended for quantitative analysis of Cdc5L expression levels across different experimental conditions. Use non-conjugated or HRP-conjugated antibodies at 1:500-1:1000 dilution. For gastric cancer studies, this method effectively demonstrates protein level changes following gene knockdown or overexpression .

Immunoprecipitation (IP): Essential for studying protein-protein interactions, particularly when investigating Cdc5L's binding partners. Studies have successfully used this approach to confirm Cdc5L's interaction with MAPK1 and securin . The agarose-conjugated format (AC) is specifically designed for this application.

Immunofluorescence (IF): Optimal for examining subcellular localization. Research has shown Cdc5L colocalizes with MAPK1 in the nucleus, providing insight into its functional domains . FITC, PE, or Alexa Fluor conjugates offer direct visualization without secondary antibodies.

Flow Cytometry: Useful for analyzing Cdc5L expression in heterogeneous cell populations or when examining cell cycle effects. PE-conjugated antibodies work particularly well for this application.

ELISA: Appropriate for high-throughput quantitative analysis when screening multiple samples.

When designing experiments, consider combining multiple detection methods to strengthen your findings, as demonstrated in recent studies examining Cdc5L's role in gastric cancer .

What is the recommended protocol for using Cdc5L antibodies in co-immunoprecipitation experiments?

Co-immunoprecipitation (Co-IP) has been instrumental in identifying Cdc5L's interaction partners, particularly MAPK1 and securin. Follow this optimized protocol based on successful research applications:

Materials:

• Cdc5L antibody (D-11) or agarose-conjugated version

• Protein A/G agarose beads (if using non-conjugated antibody)

• Cell lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, protease inhibitor cocktail)

• Wash buffer (same as lysis buffer but with 0.1% NP-40)

• SDS-PAGE loading buffer

Protocol:

• Cell lysis: Harvest cells (1-2×10^7) and lyse in 1 ml cold lysis buffer for 30 minutes on ice with occasional vortexing.

• Pre-clearing: Centrifuge lysate at 12,000×g for 10 minutes at 4°C. Incubate supernatant with 50 μl Protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Antibody binding: Add 2-5 μg of Cdc5L antibody (or 50 μl of agarose-conjugated antibody) to pre-cleared lysate and incubate overnight at 4°C with gentle rotation.

• Bead collection: If using non-conjugated antibody, add 50 μl Protein A/G beads and incubate for 2 hours at 4°C.

• Washing: Collect beads by centrifugation at 1,000×g for 1 minute, wash 4-5 times with cold wash buffer.

• Elution and analysis: Resuspend beads in SDS-PAGE loading buffer, boil for 5 minutes, centrifuge, and analyze supernatant by western blotting.

This approach has successfully demonstrated that Cdc5L immunoprecipitates with anti-MAPK1 antibody, and MAPK1 immunoprecipitates with anti-Cdc5L antibody, confirming their direct interaction .

How can researchers effectively design Cdc5L knockdown experiments in cancer cell models?

Successful Cdc5L knockdown studies in gastric cancer cells have provided valuable insights into its functional role. Follow these methodological guidelines:

siRNA/shRNA Approach:

• Design considerations: Target conserved regions of Cdc5L mRNA. For human gastric cancer cell lines (like HGC27 and MKN45), multiple siRNA sequences should be tested to identify the most effective option .

• Transfection protocol: For transient knockdown, use lipofection with siRNA at 50-100 nM concentration. For stable knockdown, lentiviral delivery of shRNA constructs provides more consistent results for long-term studies and in vivo experiments .

• Controls: Always include:

  • Negative control siRNA/shRNA with scrambled sequence

  • Positive control targeting a housekeeping gene

  • Rescue experiments with overexpression of siRNA-resistant Cdc5L to confirm specificity

• Validation methods:

  • qRT-PCR to confirm mRNA knockdown (typically 24-48 hours post-transfection)

  • Western blot to verify protein reduction (48-72 hours post-transfection)

  • Functional assays based on research question (proliferation, migration, apoptosis)

• Functional assessments: In cancer models, assess:

  • Proliferation: CCK-8 and colony formation assays

  • Migration/invasion: Transwell and wound-healing assays

  • Chemosensitivity: Cell viability with oxaliplatin treatment

  • Apoptosis: Flow cytometry with PE-Annexin V detection

For studies examining pathways regulated by Cdc5L, combine knockdown with inhibitors of relevant pathways (e.g., dabrafenib for MAPK pathway) to establish causality in observed phenotypes .

What molecular mechanisms underlie Cdc5L's role in cancer chemoresistance?

Recent studies have uncovered multiple mechanisms through which Cdc5L contributes to chemoresistance, particularly in gastric cancer:

• MAPK pathway activation: Cdc5L directly interacts with MAPK1, enhancing MAPK pathway signaling. This interaction was confirmed through co-immunoprecipitation/mass spectrometry and western blot analysis. Immunofluorescence studies further demonstrated their colocalization in the nucleus .

• Apoptosis regulation: Cdc5L knockdown significantly increases the apoptosis rate in gastric cancer cells treated with oxaliplatin. Flow cytometry analysis showed that when Cdc5L is suppressed, cells become more sensitive to chemotherapy-induced cell death .

• Cell cycle modulation: Cdc5L overexpression reduces G1 phase arrest, promoting cell cycle progression even in the presence of chemotherapeutic agents. This effect can be counteracted by MAPK1 silencing, indicating the dependency of this mechanism on MAPK pathway activation .

• DNA damage response enhancement: Gene Set Enrichment Analysis showed a positive correlation between Cdc5L expression and DNA damage response pathways. This suggests that Cdc5L helps cancer cells repair DNA damage caused by chemotherapeutic agents, thereby promoting survival .

Experimental data from in vivo studies further validate these findings. In xenograft models, combined Cdc5L knockdown and oxaliplatin treatment resulted in significantly reduced tumor volume and weight compared to control groups or single interventions. Immunohistochemistry revealed decreased Ki67 expression (a proliferation marker) and increased TUNEL staining (indicating apoptosis) in the combination treatment group .

How does Cdc5L regulate meiotic progression in oocyte maturation?

Cdc5L plays a critical role in oocyte meiotic maturation through specific molecular interactions:

• Metaphase-to-anaphase transition regulation: Knockdown experiments in mouse oocytes demonstrated that Cdc5L is essential for the metaphase-to-anaphase I transition. While Cdc5L deficiency did not affect spindle assembly, it caused metaphase I arrest and reduced first polar body extrusion .

• APC/C activity modulation: The anaphase-promoting complex/cyclosome (APC/C) is crucial for cell cycle progression. Cdc5L knockdown resulted in insufficient APC/C activity, preventing proper cell cycle advancement .

• Securin interaction: Cdc5L directly interacts with securin, a protein that inhibits separase activity until the appropriate time for chromosome separation. This interaction was confirmed through experimental approaches, revealing a novel regulatory mechanism .

• Securin degradation control: In normal meiotic progression, securin is degraded to allow chromosome separation. Cdc5L knockdown led to persistently high securin levels, compromising meiotic progression. Most significantly, this arrest could be rescued by simultaneous knockdown of endogenous securin, confirming the causative relationship .

These findings establish Cdc5L as a critical factor for proper oocyte maturation, with potential implications for fertility research and assisted reproductive technologies. The studies employed rigorous methodologies, including siRNA injection into immature germinal vesicle (GV) oocytes collected from hormone-primed mice, followed by detailed analysis of meiotic progression markers .

What advanced techniques are being used to study Cdc5L interactions in cellular signaling pathways?

Researchers are employing sophisticated techniques to elucidate Cdc5L's role in cell signaling:

• Co-IP/Mass Spectrometry: This combined approach has identified novel Cdc5L interaction partners, including MAPK1. The workflow involves immunoprecipitation with anti-Cdc5L antibody followed by mass spectrometric analysis of co-precipitated proteins, revealing previously unknown functional connections .

• Proximity Ligation Assays (PLA): While not explicitly mentioned in the provided sources, this technique represents an advanced alternative to traditional co-immunoprecipitation for detecting protein-protein interactions in situ, offering spatial resolution of interactions within cells.

• Fluorescence Co-localization Analysis: Immunofluorescence studies have demonstrated the co-localization of Cdc5L and MAPK1 in the nucleus, providing spatial context for their interaction. This technique complements biochemical approaches by showing where in the cell these interactions occur .

• Functional Rescue Experiments: Advanced experimental designs include knockdown of one protein (e.g., Cdc5L) followed by overexpression of an interaction partner (e.g., MAPK1) to determine functional relationships. These studies have shown that MAPK1 silencing impedes gastric cancer cell proliferation, which can be rescued by Cdc5L overexpression .

• Organoid Models: This three-dimensional culture system more accurately represents in vivo environments than traditional cell cultures. Research has shown that MAPK1 silencing inhibits organoid growth, which can be reversed by Cdc5L overexpression, demonstrating the relevance of this interaction in complex tissue-like structures .

• Xenograft Models with Genetic Manipulation: In vivo studies utilizing nude mice with various genetic manipulations (e.g., NC, shCdc5L, shCdc5L+vector, shCdc5L+oeMAPK1) have provided compelling evidence for the functional significance of Cdc5L-MAPK1 interaction in tumor growth .

These advanced techniques collectively enable a more comprehensive understanding of Cdc5L's role in cellular signaling networks.

What are common technical challenges when detecting Cdc5L in different experimental systems?

Researchers may encounter several challenges when working with Cdc5L antibodies:

• Cross-reactivity concerns: Cdc5L has structural similarities with other proteins in the CDC5 family. When selecting antibodies, verify specificity through validation studies or knockout controls. The D-11 clone has demonstrated specificity across mouse, rat, and human samples .

• Signal variability in western blotting: Optimal detection often requires:

  • Membrane blocking with 5% non-fat milk in TBST for 1 hour at room temperature

  • Primary antibody dilution at 1:500-1:1000 (for 200 μg/ml concentration)

  • Overnight incubation at 4°C for maximum sensitivity

  • HRP-conjugated secondary antibody (if using non-conjugated primary)

  • Enhanced chemiluminescence detection

• Immunofluorescence optimization: For nuclear proteins like Cdc5L:

  • Ensure proper fixation (4% paraformaldehyde for 15 minutes)

  • Include a permeabilization step (0.2% Triton X-100 for 10 minutes)

  • Use appropriate counterstains for nuclear visualization (DAPI)

  • Consider confocal microscopy for precise subcellular localization

• Variability in knockdown efficiency: When designing siRNA/shRNA experiments:

  • Test multiple targeting sequences

  • Optimize transfection conditions for each cell type

  • Monitor knockdown duration to plan experiments appropriately

  • Include appropriate positive and negative controls

• Co-immunoprecipitation challenges: For protein interaction studies:

  • Use gentle lysis conditions to preserve protein complexes

  • Include appropriate negative controls (IgG from same species)

  • Consider crosslinking for transient interactions

  • Validate results with reverse co-IP (precipitate with antibody against interacting partner)

How can researchers quantitatively assess Cdc5L's effects on cell cycle and apoptosis?

Quantitative assessment of Cdc5L's impact on cellular processes requires rigorous methodological approaches:

Cell Cycle Analysis:

• Flow cytometry protocol:

  • Harvest cells 48-72 hours post-transfection

  • Fix in 70% ethanol at -20°C overnight

  • Stain with propidium iodide (50 μg/ml) containing RNase A

  • Analyze using standard cell cycle program on flow cytometer

  • Quantify percentage of cells in G0/G1, S, and G2/M phases

• Western blot analysis of cycle-related proteins:

  • Monitor expression of cyclins (D1, E, B1)

  • Assess CDK levels and phosphorylation status

  • Evaluate p21 and p27 expression as cell cycle inhibitors

  • Use housekeeping proteins (β-actin, GAPDH) as loading controls

Apoptosis Assessment:

• Flow cytometry with PE-Annexin V/PI staining:

  • Collect cells (including floating cells) 24-48 hours post-treatment

  • Wash with PBS and resuspend in binding buffer

  • Stain with PE-Annexin V and propidium iodide

  • Analyze within 1 hour, distinguishing early apoptotic (Annexin V+/PI-) from late apoptotic (Annexin V+/PI+) cells

• TUNEL assay for in vivo and tissue samples:

  • Process tissue sections according to standard protocols

  • Use immunofluorescence detection for quantification

  • Calculate percentage of TUNEL-positive cells

In published studies, these methods have effectively demonstrated that Cdc5L knockdown increases apoptosis rates in gastric cancer cells treated with oxaliplatin, with flow cytometry results showing a dramatic increase in the apoptosis rate in Cdc5L-silenced groups . Similarly, in vivo studies using immunohistochemistry and immunofluorescence analysis revealed decreased Ki67 expression and significantly increased TUNEL staining in Cdc5L knockdown tumors treated with chemotherapy .

What experimental controls are essential when investigating Cdc5L function through antibody-based techniques?

Rigorous experimental design requires appropriate controls to ensure reliable results when studying Cdc5L:

Western Blotting Controls:

• Loading controls: Include housekeeping proteins (β-actin, GAPDH, or α-tubulin) to normalize for total protein content.

• Molecular weight marker: Confirm Cdc5L's expected molecular weight (~92 kDa).

• Positive control: Include a sample known to express Cdc5L (e.g., HeLa cells).

• Negative control: When possible, include lysate from Cdc5L-knockout or effectively silenced cells.

• Antibody specificity control: Pre-incubation with blocking peptide if available.

Immunofluorescence Controls:

• Primary antibody omission: Detect non-specific binding of secondary antibody.

• Isotype control: Use non-specific IgG of same isotype and concentration.

• Subcellular marker co-staining: Include nuclear markers (DAPI) to confirm expected localization.

• Knockdown verification: Compare staining in Cdc5L-silenced cells.

Co-Immunoprecipitation Controls:

• Input sample: Include unprocessed lysate (5-10%) to confirm protein presence.

• IgG control: Use non-specific IgG from the same species instead of specific antibody.

• Reverse co-IP: Precipitate with antibody against the interacting partner and probe for Cdc5L.

• Specificity control: Perform co-IP after knockdown of one interaction partner.

Functional Assays Controls:

• Vector control: Include empty vector control when overexpressing Cdc5L.

• Scrambled siRNA/shRNA: Use non-targeting sequence when performing knockdown.

• Rescue experiment: Re-express siRNA-resistant Cdc5L to confirm phenotype specificity.

• Pathway inhibitor controls: Include specific inhibitors (e.g., dabrafenib for MAPK pathway) to confirm pathway involvement.

These controls have been effectively implemented in studies examining Cdc5L's interactions with MAPK1 in gastric cancer cells and with securin in oocyte maturation, demonstrating their importance in establishing specific biological effects .